129 related articles for article (PubMed ID: 38009394)
21. Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Skoneczna I; Marreaud S; de Wit R; Sylvester R
J Clin Oncol; 2009 Nov; 27(33):5634-9. PubMed ID: 19786668
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial.
Spigel DR; Jotte RM; Aix SP; Gressot L; Morgensztern D; McCleod M; Socinski MA; Daniel D; Juan-Vidal O; Mileham KF; West H; Page R; Reinmuth N; Knoble J; Chen T; Bhore R; Wolfsteiner M; Ong TJ; Gridelli C; Thomas M;
Clin Lung Cancer; 2021 Jan; 22(1):6-15.e4. PubMed ID: 33097414
[TBL] [Abstract][Full Text] [Related]
23. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
[TBL] [Abstract][Full Text] [Related]
24. Gemcitabine Plus Cisplatin Split
Izumi K; Iwamoto H; Yaegashi H; Shigehara K; Nohara T; Kadono Y; Mizokami A
In Vivo; 2019; 33(1):167-172. PubMed ID: 30587618
[TBL] [Abstract][Full Text] [Related]
25. The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Tully CM; Apolo AB; Zabor EC; Regazzi AM; Ostrovnaya I; Furberg HF; Rosenberg JE; Bajorin DF
Cancer; 2016 Mar; 122(5):712-21. PubMed ID: 26618338
[TBL] [Abstract][Full Text] [Related]
26. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Hainsworth JD; Meluch AA; Litchy S; Schnell FM; Bearden JD; Yost K; Greco FA
Cancer; 2005 Jun; 103(11):2298-303. PubMed ID: 15856431
[TBL] [Abstract][Full Text] [Related]
28. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S
Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Huang J; Su R; Chen Z; Jiang S; Chen M; Yuan Y; Hu H; Fu C; Huang Z; Wang Z; Zheng B; Li C; Wang Z; Bao Y; Cai M; Guo J; Wei Q; Xue W
Oncoimmunology; 2022; 11(1):2124691. PubMed ID: 36148322
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
31. Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
Kim YR; Lee JL; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
Cancer Chemother Pharmacol; 2015 Jul; 76(1):141-53. PubMed ID: 26001531
[TBL] [Abstract][Full Text] [Related]
32. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.
Liu GY; Ye YF; Jiang YF; Chen GJ; Xia WX; Huang YS; Gao TS; Liu YM; Hou YT; Li JF; Liu JH; Lu N; Chen CL; Ke LR; Liang H; Bei WX; Li WZ; Dong SH; Liu Q; Xie C; Yao HR; Xiang YQ
BMJ; 2024 Jun; 385():e077890. PubMed ID: 38897625
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
34. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
De Santis M; Bellmunt J; Mead G; Kerst JM; Leahy M; Maroto P; Gil T; Marreaud S; Daugaard G; Skoneczna I; Collette S; Lorent J; de Wit R; Sylvester R
J Clin Oncol; 2012 Jan; 30(2):191-9. PubMed ID: 22162575
[TBL] [Abstract][Full Text] [Related]
35. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
Bamias A; Lainakis G; Kastritis E; Antoniou N; Alivizatos G; Koureas A; Chrisofos M; Skolarikos A; Karayiotis E; Dimopoulos MA
Oncology; 2007; 73(5-6):290-7. PubMed ID: 18477854
[TBL] [Abstract][Full Text] [Related]
36. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Linardou H; Aravantinos G; Efstathiou E; Kalofonos C; Anagnostopoulos A; Deliveliotis C; Bafaloukos D; Athanasios Dimopoulos M; Bamias A;
Urology; 2004 Sep; 64(3):479-84. PubMed ID: 15351574
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
38. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
[TBL] [Abstract][Full Text] [Related]
39. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
40. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
